Patrícia Silva, PhD, director of science content —

Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles.

Articles by Patrícia Silva

FDA Grants Orphan Drug Status to CF Therapy Now in Phase 2 Study

The U.S. Food and Drug Administration (FDA) has designated Concert Pharmaceuticals‘ next-generation therapy, CTP-656, an Orphan Drug to treat cystic fibrosis (CF). CTP-656 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that, according to the company’s website, was developed by applying deuterium chemistry to modify Kalydeco (ivacaftor).  Concert has said…

First Allied Securities Donates $73,000 to Cystic Fibrosis Foundation

First Allied Securities has given the Cystic Fibrosis Foundation a $73,487 donation for research and programs dealing with the disease. Archie Manning, a retired National Football League quarterback, donated memorabilia that First Allied’s charity arm, First Philanthropy, auctioned for some of the donation. In the past seven years, First Philanthropy has…

Australian Research Group Aiming for Better Ways of Treating Biofilm Infections

Scientists at the University of Queensland, Australia, are focusing their efforts on what is one of world’s leading sources of antibiotic resistance — biofilm. Biofilms refer to the communities of bacteria and other microorganisms that adhere to surfaces in thin layers and secrete a protective coating that diminishes the effects of antibiotics. Biofilms are considered…